Saroja Pharma Industries India Ltd (SAROJA) — shareholding pattern, promoter holding, financials and share price
About Saroja Pharma Industries India Ltd (SAROJA)
Saroja Pharma Industries India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SAROJA and on the BSE under scrip code 91651. Its ISIN is INE0PCL01011.
Incorporated in 2023, Saroja Pharma Ltd is mainly in the business of trading Thionyl Chloride chemical and pharmaceutical intermeddles, etc. [1]
Saroja Pharma Industries India Limited is primarily engaged in providing pharmaceutical services, focusing on the trade of Active Pharmaceutical Ingredients (API), Pharma Intermediates, and other chemical products used in human and veterinary medicine.
The company has recently transitioned from a private to a public limited entity, intending to leverage its new structure to access broader market opportunities and increase its investor base.
Listed peers in Pharmaceuticals: Zenith Health Care Ltd, Dipna Pharmachem Ltd, Starsource Multitrade Ltd, Ortin Global Ltd, Beryl Drugs Ltd, Unjha Formulations Ltd.
Valuation & Returns
At ₹30 a share, Saroja Pharma Industries India Ltd (SAROJA) was valued at a price-to-earnings ratio of 7.83x against an industry P/E of 36.41x and a price-to-book of 0.73x on a book value of ₹43.01 per share. Solomo computes return on equity of 9.36% and return on capital employed of 11.66% from filed results.
- P/E
- 7.83x
- Industry P/E
- 36.41x
- P/B
- 0.73x
- EPS (TTM)
- ₹2.57
- Book value / share
- ₹43.01
- ROE
- 9.36%
- ROCE
- 11.66%
- ROA
- 3.86%
- Debt / equity
- 0.83x
- Dividend yield
- 0%
- EBITDA margin
- 5.43%
- 52-week range
- ₹28 – ₹60
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Saroja Pharma Industries India Ltd (SAROJA) reported revenue of ₹70.24 crore, net profit of ₹1.62 crore and earnings per share of ₹4.03. That compares with revenue of ₹53.73 crore and net profit of ₹1.03 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹31.47 crore and net profit ₹1.04 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 55.63 | 50.19 | 40.67 | 53.73 | 70.24 |
| Net profit (₹ cr) | 1.14 | 1.06 | 0.88 | 1.03 | 1.62 |
| EPS (₹) | 50.49 | 3.61 | 2.19 | 2.56 | 4.03 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | -1.16% | 32.11% |
| Profit growth | -3.20% | 17.05% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 73.02% of Saroja Pharma Industries India Ltd (SAROJA). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
Largest disclosed public shareholders in Mar 2026: SWASTIKA INVESTMART LTD 1.99%, KAMLESH NATWARLAL SHAH 1.31%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 73.02% | - | - | - | - |
| Sep 2025 | 73.02% | - | - | - | - |
| Mar 2025 | 73.02% | - | - | - | - |
| Sep 2024 | 73.02% | - | - | - | - |
| Mar 2024 | 73.02% | - | - | - | - |
| Sep 2023 | 73.02% | - | - | - | - |